We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 45

Pfizer v Ratiopharm, appeal of decision on invalidity, Amlodipine Besylate, July 29, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 26 2010

In the Federal Court, Pfizer's patent for amlodipine besylate was held invalid on numerous grounds, including obviousness


Merck v. Pharmascience, PMNOC Regulations decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

The Court, in a lengthy decision, dismissed an application for prohibition in respect of the drug finasteride, wherein allegations of invalidity had been raised, including grounds of double-patenting, novelty and obviousness


Apotex v Sanofi, case management directions on the late disclosure of documents or information
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question


Apotex loses the war in Canada and the battle in England: UK courts rely on Canadian decision to find Apotex acting unlawfully in cCnada has consequences in eErope
  • Gowling Lafleur Henderson LLP
  • Canada, United Kingdom
  • October 13 2011

Servier developed perindopril erbumine (“perindopril”) which is a successful long lasting ACE inhibitor sold under the trade-mark COVERSYL


Janssen-Ortho v. Apotex, recusal by the judge, levofloxacin, June 14, 2010; motion to dismiss granted, levofloxacin, June 29, 2010
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 16 2010

In a PMNOC case, Justice Shore granted an order of prohibition against Apotex in respect of its levofloxacin until patent expiry


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Impacts of the Amazon.com decisions on medical use claims in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 13 2012

Methods of medical treatment and surgery are not statutory subject matter in Canada


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling Lafleur Henderson LLP
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing


Novopharm v. Eli Lilly, appeals of decisions of the Case Management Prothonotary
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Eli Lilly appealed two interlocutory decisions made by the Case Management Prothonotary